Skip to main content
OpenTrials
Completed

NCT Number: NCT00762086

Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II

The purpose of this study is to evaluate the safety and efficacy of new intermittent pneumatic compression device on initial claudication distance in patients with Peripheral Arterial Disease stage II

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Praxis für Angiology, Munich, Germany

Loading trial locations.

About this study

Patients with Peripheral Arterial Disease (PAD) suffer from symptoms such as intermittent claudication, limb and foot pain and tissue lesions, which are difficult to treat. In recent years, there have been reports demonstrating reduction of these symptoms by use of compressible sleeve devices.

This clinical study aims at demonstrating the safety and effectiveness of this device in treating PAD symptoms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subject 18 to 90 years, of any race.
  • Patients with proven Peripheral Arterial Disease (PAD) in Doppler Ultrasound and Ankle-Brachial Pressure Index (ABPI ≤ 0.9 in one leg)
  • Subject with stable (>3 month) PAD Fontaine Stage II.
  • Aortoiliac vessels with no significant hemodynamic disturbances , as confirmed by recent (<30 days) clinical examination
  • Subject has intermittent claudication and claudication pain of the calf
  • Subject has stable intermittent claudication (>3 month and not more than one year) with initial claudication distance not more than 250 meters, as determined by treadmill test (3.2 km/h, 10% grade)
  • Subject willing to participate as evidenced by signing the written informed consent.
  • Treatment with Aspirin or Clopidogrel for at least 7 days
  • Willingness to undergo standardized walking exercise

Exclusion criteria

  • Ankle-Brachial Pressure Index (ABI) above 0.8 in both legs. In Diabetic patients with no compressible arteries ABI above 40 mm/Hg of the higher pressure measured in both arms.
  • Inability to walk
  • Chronic respiratory insufficiency (severe obstructive or restrictive)
  • Coronary artery disease with angina
  • Stroke, myocardial infarction or other acute vascular events in the last 3 months
  • Mild-Severe congestive heart failure
  • Degenerative or inflammatory hip, knee, ankle or foot joint lesions interfering with walking
  • Spinal stenosis or disc lesions with lower limb motor sensory defects
  • Leg trauma, limb or skin infection or edema
  • Recent (6 months) abdominal, cardiothoracic, vascular or orthopedic (lower limb) surgery
  • Subject after crural or pedal bypass surgery
  • Subject with neuropathy
  • Uncontrolled arterial hypertension
  • Morbid obesity (BMI >35.0)
  • Need for concomitant medication with potential vascular activity
  • Routinely use of pain relief medications (i.e. NSAIDs, Narcotics etc)
  • Expected weak compliance
  • Subject requires surgical or endovascular intervention for PAD
  • Subject has known allergy to device components (sleeve fabric).
  • Subject has medical conditions that may be worsened by concomitant use of the device (i.e. recent (1 year) Deep Vein Thrombosis).
  • Subject participates in any other clinical study at the same time

Treatment and study plan

AngioPress Intermittent pneumatic compression (IPC) Device

Device

Treatment with Intermittent pneumatic compression (IPC) for PAD

Medications and Standard walking exercises

Other

Aspirin/Clopidegrol and Standard walking exercises

Primary outcomes

  1. Absolute Claudication Distance (ACD)

    Time frame: 3 months

    Absolute walking distance is measured by walking on a treadmill until the point when the subject is inable to walk anymore due to pain in the leg. The walking distance is measured by meters

Sponsors and collaborators

Lead sponsor

Mego Afek Ltd.

Industry

Registry information

Official study title

A Prospective, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of a New Intermittent Pneumatic Compression Device on Initial Claudication Distance in Patients With Peripheral Arterial Disease Stage II.

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Sep 30, 2008
Registry last updated
Aug 31, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.